Verastem - Stock Price History | VSTM

Historical daily share price chart and data for Verastem since 2021 adjusted for splits. The latest closing stock price for Verastem as of September 27, 2021 is 3.21.
  • The all-time high Verastem stock closing price was 17.57 on July 10, 2013.
  • The Verastem 52-week high stock price is 4.93, which is 53.6% above the current share price.
  • The Verastem 52-week low stock price is 1.14, which is 64.5% below the current share price.
  • The average Verastem stock price for the last 52 weeks is 2.63.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Verastem Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 1.8334 1.3300 4.2000 1.1100 2.1300 58.96%
2019 1.9169 3.6100 4.0900 0.8604 1.3400 -60.12%
2018 5.4418 3.2100 9.9700 2.8800 3.3600 9.45%
2017 2.7902 1.1500 5.4100 1.1300 3.0700 174.11%
2016 1.3475 1.7800 1.8600 1.0700 1.1200 -39.78%
2015 6.4943 9.4500 12.1000 1.6100 1.8600 -79.65%
2014 9.9942 12.4800 16.2100 7.1400 9.1400 -19.82%
2013 11.3766 9.9000 17.5700 8.7900 11.4000 29.69%
2012 9.4706 11.0900 12.0100 6.4700 8.7900 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.580B $0.089B
Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29